Offer - Urjas Oil for just ₹ 1 X
Oxipod CV Tablet is a prescription drug, available for use as Tablet. Secondary and off-label uses of Oxipod CV Tablet have also been mentioned below.
Medical history of the patient along with age and gender determines the dosage of Oxipod CV Tablet. The condition it has been prescribed for, and the route of administration also determine the right dosage. This information has been provided in detail in the dosage section.
Apart from the aforementioned side effects, Oxipod CV Tablet can also lead to other problems, which have been listed below. Such side effects of Oxipod CV Tablet normally do not last long and go away once the treatment is completed. Please speak with your doctor if these side effects worsen or persist for a longer duration.
In addition, Oxipod CV Tablet's effect is Mild during pregnancy and Moderate for lactating mothers. In addition, Oxipod CV Tablet's effects on the liver, heart and kidney are discussed below in the Oxipod CV Tablet related warnings section.
Individuals suffering from medical conditions like Jaundice must refrain from the use of Oxipod CV Tablet since this can cause severe adverse effects. Other conditions have been mentioned below in the Oxipod CV Tablet contraindications section.
Besides this, Oxipod CV Tablet may also have severe interaction with some medicines. A complete list of these interactions is given below.
You should also be aware that Oxipod CV Tablet is safe while driving, and is addiction.
Oxipod CV Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
Adult |
|
Geriatric |
|
Is the use of Oxipod CV Tablet safe for pregnant women?
Oxipod Cv rarely shows harmful effects in in pregnant ladies. Even if it does, the effects are mild
Is the use of Oxipod CV Tablet safe during breastfeeding?
Women who are breastfeeding can experience some moderate side effects of Oxipod Cv. Immediately discontinue Oxipod Cv if you observe any side effects. Contact your doctor, and restart using it only if your doctor considers it safe for you.
What is the effect of Oxipod CV Tablet on the Kidneys?
There can be some harmful effects on your kidneys after taking Oxipod Cv. If you witness any side effects, discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Oxipod CV Tablet on the Liver?
The liver can be affected by Oxipod Cv. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart Oxipod Cv only after medical advice.
What is the effect of Oxipod CV Tablet on the Heart?
Side effects of Oxipod Cv rarely affect the heart.
Oxipod CV Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Oxipod CV Tablet unless your doctor advises you to do so -
Is this Oxipod CV Tablet habit forming or addictive?
No, there is no any evidence that Oxipod CV Tablet is addictive.
Interaction between Food and Oxipod CV Tablet
You can take Oxipod CV Tablet with food.
Interaction between Alcohol and Oxipod CV Tablet
No research has been done on this till date. Therefore, it is not known what the effect of taking Oxipod CV Tablet with alcohol will be.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311